Skip to main content

iTeos Therapeutics, Inc.

ITOSDelisted Aug 29, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001808865

iTeos Therapeutics, Inc. was delisted on Aug 29, 2025; its insiders filed their last Form 4 on Aug 29, 2025; 137 institutions reported holding it in 13F filings for Q2 2025, worth $377.0M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
137
Q2 2025, +5 vs. previous quarter
13F value
$377.0M
Reported value at the end of Q2 2025
Superinvestors holding
0
At the end of Q2 2025

From SEC filings, in USD.

Revenue, FY2024
$35.0M
+177.9% year over year
Net income, FY2024
-$134.4M
No comparable prior period
Free cash flow, FY2024
-$99.8M
No comparable prior period
Revenue, Q2 FY2025
$0
−100.0% year over year

Revenue flow, FY2024

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2024: $134.4M (384.0% of revenue).

Superinvestors holding ITOS, Q2 2025

Go to the superinvestors tab

No superinvestor reported holding ITOS at the end of Q2 2025.

Latest insider trades

See all insider trades

Open-market purchases and sales by iTeos Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 11, 2025 (view filing)Jun 9-102 daysDetheux MichelChief Executive OfficerSSale−16.8K$10.03−$168.4K−11.0%135.9K after2 lots10b5-1
Jun 11, 2025 (view filing)Jun 9-102 daysDetheux MichelChief Executive OfficerSSale−87.8K$10.02−$879.8K−100.0%0 after2 lots10b5-1
Jun 6, 2025 (view filing)Jun 4-62 daysDetheux MichelChief Executive OfficerSSale−25.2K$10.15−$255.9K−15.6%135.9K after3 lots10b5-1
Jun 6, 2025 (view filing)Jun 4-62 daysDetheux MichelChief Executive OfficerSSale−131.6K$10.15−$1.34M−100.0%0 after3 lots10b5-1
Jun 6, 2025 (view filing)Jun 4-62 daysHallal DavidDirectorSSale−114.7K$10.15−$1.16M−100.0%0 after3 lots10b5-1
May 16, 2025 (view filing)May 14-152 daysEcoR1 Capital, LLC10% OwnerPPurchase+4.96M$7.80+$38.7M+86.5%10.7M after2 lots
May 15, 2025 (view filing)5:34 PM ETMay 132 daysGadicke Ansbert and 3 othersOther: Former 10% OwnerSSale−1.03M$8.06−$8.32M−23.0%3.45M after
May 15, 2025 (view filing)5:33 PM ETMay 132 daysMPM Bioventures 2018, L.P. and 2 othersOther: Former 10% OwnerSSale−630.2K$8.06−$5.08M−23.0%2.11M afterDuplicate filing
May 15, 2025 (view filing)5:32 PM ETMay 132 daysEvnin Luke and 8 othersOther: Former 10% OwnerSSale−630.2K$8.06−$5.08M−23.0%2.11M after
Nov 19, 2024 (view filing)Nov 19Same dayGall MatthewChief Financial OfficerPPurchase+5.00K$7.73+$38.6K+8.3%65.4K after

Top 10 13F holders, Q2 2025

See all 137 holders

The largest institutional positions in iTeos Therapeutics, Inc. at the end of Q2 2025; share changes are against Q1 2025.

Institutions holding ITOS in Q2 2025
InstitutionSharesValue% of portfolioChange in sharesAction
EcoR1 Capital, LLC10,688,978$106.6M6.32%+10,688,978New
BlackRock, Inc.4,574,537$45.6M0.00%+65,290+1.4%Added
Tang Capital Management LLC3,826,692$38.2M1.93%+1,137,492+42.3%Added
Vanguard Group Inc1,664,161$16.6M0.00%−62,297−3.6%Reduced
Dimensional Fund Advisors LP832,761$8.30M0.00%−348,493−29.5%Reduced
Boxer Capital Management, LLC825,000$8.23M4.14%+825,000New
Geode Capital Management, LLC703,467$7.02M0.00%+53,414+8.2%Added
OrbiMed Advisors LLC700,000$6.98M0.18%+700,000New
Marshall Wace, LLP611,649$6.10M0.01%+492,091+411.6%Added
Renaissance Technologies LLC602,100$6.00M0.01%−43,500−6.7%Reduced

Holders of 5% or more of ITOS

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of iTeos Therapeutics, Inc..

Largest holders of ITOS from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Tang Capital Management LLC13D/A100.00%10.0K shares+90.01 ppfrom 9.99%Sep 30, 20246 filingsSep 3, 2025SEC
EcoR1 Capital, LLC13D27.90%10.7M shares+13.00 ppfrom 14.90%Feb 16, 20245 filingsMay 16, 2025SEC
BlackRock Portfolio Management LLC13G6.10%2.33M sharesNewApr 15, 20251 filingApr 15, 2025SEC
BlackRock, Inc.13G/A5.70%2.18M shares–Oct 21, 20243 filingsApr 23, 2025SEC